

20
27 PROGRAM

PHARM.D. FELLOWSHIP



Contents

Why Daiichi Sankyo?

• Company Overview	3
• A Legacy of Innovation Since 1899	4
• Company at a Glance	4
• Values & Behaviors	5
• A Message from Our U.S. President	6
• How WeTHRIVE	7
• Why This Mid-Sized Company?	8
• The Fellowship Experience	9
• Past Fellow Perspectives	10
• Fellowship Alumni	11
• Fellowship Leadership Team	12
• Fellowship Steering Committee	13
• Co-Chief Fellows	14
• Fellow Committee Leads	15

Recruiting Fellowships

• Clinical Science (CS)	17
<i>Three, 2-Year Positions</i>	
• Global Oncology Medical Affairs (GOMA)	23
<i>One, 2-Year Position</i>	
• Global Regulatory Affairs (GRA)	27
<i>One, 2-Year Position</i>	
• U.S. Marketing (USM)	31
<i>One, 2-Year Position</i>	
• U.S. Medical Affairs (USMA) Oncology	35
<i>One, 2-Year Position</i>	
• U.S. Training & Development (T&D)	39
<i>One, 2-Year Position</i>	

Non-Recruiting Fellowships

• Companion Diagnostics (CDx)	44
• Global Business Development (GBD) Transactions & Marketing	45
• Global Clinical Safety & Pharmacovigilance (GCSPV)	46
• Global Oncology Health Economics & Outcomes Research (HEOR) & Real-World Evidence (RWE)	47
• Global Oncology Marketing (GOM)	48
• Global Oncology Pricing, Reimbursement & Access (PRA)	49
• Global Regulatory Labeling Strategy (GRLS)	50
• Quality Assurance Good Manufacturing Practices (QA GMP)	51
• Translational Science (TS)	52

Rutgers Pharmaceutical Industry Fellowship (RPIF)

• Leadership	54
• Program History & Professional Development Series	55
• Key Program Features & Application Process and Eligibility Requirements	56
• RPIF Chief Fellow Perspectives	57

PHARM.D.
FELLOWSHIP

Company Overview



HEADQUARTERS

★ **U.S.** Daiichi Sankyo, Inc.
211 Mt. Airy Road,
Basking Ridge, NJ 07920
Phone: +1 908 992 6400

🌐 **GLOBAL** Daiichi Sankyo Co., Ltd.
3-5-1, Nihonbashi Honcho,
Chuo-ku, Tokyo, 103-8426 Japan

Our Vision: To Be an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society

At Daiichi Sankyo, we create essential medicine for longer, better lives. Every day, we strive to put our skills at the service of those in need. We unite cutting-edge science and technology with unwavering dedication and care to develop life-changing solutions for our patients.

We rely on reason, ingenuity, perseverance, and empathy to make bold strides in oncology and will continually rise to the challenges ahead.

We owe our success to the collaboration between our people, scientists, healthcare providers and advocates. Thanks to their passionate expertise, they are all essential partners on our journey. Building on our heritage and a culture of innovation since 1899, our 20K+ employees are forging better futures through medicine for people everywhere.

Together, we are creating new standards of care—our contribution to the enrichment of quality of life around the world.

Please visit DaiichiSankyo.us for U.S.-specific information, or DaiichiSankyo.com for a global view.





A Legacy of Innovation Since 1899

Recognized Leader in Medicine for More Than a Century

Our heritage of scientific discovery spans since 1899 – from the discovery of epinephrine (adrenaline) and the development of the statin class of lipid-lowering agents to the development of the first glitazone that revolutionized long-term control of type 2 diabetes.

Our parent company, Daiichi Sankyo Co., Ltd., was established in 2005 with the merger of two leading century-old pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products that address the unmet medical needs of patients in mature and emerging markets. Today, our products help patients in more than 30 countries/regions around the world, including North America, Japan, Asia, Latin America and Europe.

Our Legacy in the U.S.

The thousands of cherry trees that line the tidal basin in West Potomac Park in Washington, D.C. aren't a natural phenomenon. They represent a cross-cultural partnership between the United States and Japan that was forged more than 100 years ago.

In 1912, world-famous chemist and our company's first president, Dr. Jokichi Takamine gifted 3,000 cherry trees from Mayor Yukio Ozaki of Tokyo to the city of Washington, D.C. as a symbol of harmony between our two nations.

U.S. subsidiary Daiichi Sankyo, Inc., began operating in the U.S. in 2006 as a member of the Daiichi Sankyo Group. Not only is the gift an important symbol of global collaboration, but it is an important part of our history and Dr. Takamine's legacy, whose collaborative role continues to inspire our company today.

COMPANY AT A GLANCE

A legacy of innovation since
1899

20,000+
employees around the world

¥2,123.0B**
FY2025 consolidated revenue

Global
innovative pharmaceutical company

23rd
Ranked among top global
pharmaceutical companies*

Ground presence in
32
countries/regions

Manufacturing in
6
countries/regions

22 R&D
sites in key locations

* 2025 Pharm Exec Top 50 Companies | Pharmaceutical Executive, 06-14-2025, Volume 45, Issue 5

** Based on exchange rate around March 31, 2026 (~ 158.7 JPY/USD, reported FY2025 revenue of JPY 2,123 billion converts to approximately \$13.4-\$13.5 billion USD. Consolidated Financial Results for Fiscal 2025 (Year Ended March 31, 2026).



Values & Behaviors

Core Daiichi Sankyo values and behaviors are the guiding principles that direct decision-making. They speak to what is important to the organization and the individuals, along with what patients, customers and employees can expect.


Core Values

- Innovation**
The introduction of new ideas, methods, or invention
- Integrity**
The quality of being honest and of always having high moral principles
- Accountability**
Being responsible for the effects of your actions, and being willing to explain or be criticized for them



Core Behaviors

- Be Inclusive & Embrace Diversity**
We value people for who they are as individuals, and welcome diverse perspectives in our work, which enables us to achieve more as Daiichi Sankyo
- Collaborate & Trust**
We treat each other with respect and build trust through transparency and willingness to listen, which enables us to collaborate simply and productively
- Develop & Grow**
We learn, experiment, and take initiative, which enables us to grow together every day and strengthen Daiichi Sankyo's capability



A Message from Our U.S. President

“Daiichi Sankyo is a unique, global organization that has a rich history of innovation, research and discovery. As our people embrace challenges, we support them in seeking new opportunities and growing their careers. Fellows thrive in the culture we have built at Daiichi Sankyo and begin contributing to our mission, to bring new, meaningful medicines to the world, from day one.”

Ken Keller

Global Head, Oncology Business President & CEO, Daiichi Sankyo, Inc.



HOW WeTHRIVE

At Daiichi Sankyo, we aim to empower you to take an active role in managing your well-being.

WeTHRIVE evolves our ways of working, improves work-life harmony and has become a key element of our culture.

Why WeTHRIVE?

WeTHRIVE began company wide in 2021 and is one reflection of leadership's commitment to the well-being of employees. Being our best for patients starts with taking care of our own well-being. While there's no magic approach to doing this, there are small steps we can all take together that can make a big impact.

Empowering Employees to Thrive

WeTHRIVE is a fundamental part of our culture where employees are accountable for actively engaging in their well-being, fostering work-life harmony, and utilizing provided resources to create a supportive environment where everyone's well-being is valued and prioritized.



*Applies to all non-field-based employees of Daiichi Sankyo

**Does not apply to field employees—field employees have July 4 De-Stressor Week

While fellows are employed through Rutgers University, WeTHRIVE is reflective of culture considerations for their work at Daiichi Sankyo.

Why This Mid-Sized Company?

At Daiichi Sankyo, Inc., our people are our greatest asset and by investing in inclusive practices across the organization we are able to bring the best medicines to our patients.

- Individualized experience aligned with fellows' interests
- Broad support throughout the organization
- Close interactions with high-level management and peers
- Many opportunities to lead, rotate and/or assist with projects in various areas of the business to gain exposure to different areas of the pharmaceutical industry
- Open and approachable leaders
- Comfortable, flexible and supportive work environment

The Fellowship Experience



Past Fellow Perspectives

TAKEAWAYS



- Real-world learning led by knowledgeable mentors
- Grow as a leader by tackling complex projects

Pooja Vekaria,
Pharm.D., R.Ph., RUCIF

*2022-2024 Global Regulatory Affairs Fellow
Rutgers University,
Ernest Mario School of Pharmacy*



- Unwavering senior leadership support
- Contribute to key impactful deliverables

Jahmal Williams,
Pharm.D., R.Ph., RUCIF

*2023-2025 Global Oncology
Medical Affairs Fellow
Husson University School of Pharmacy*



- Culture of mentorship and growth
- Opportunity to make key contributions

Andrew Perez-Viñas,
Pharm.D., M.B.A., RUCIF

*2021-2023 U.S. Medical Affairs Fellow
Farleigh Dickinson University*



- Deliver results through patient-centered projects
- Collaborate across functions to build critical thinking and adaptability

Libby Shelton,
Pharm.D., R.Ph., RUCIF

*2023-2025 U.S. Training & Dev. Fellow
Purdue University College of Pharmacy*



- Company culture that values integrity and accountability
- Supportive mentors committed to personal and professional development

Jacqueline Conti,
Pharm.D., R.Ph., RUCIF

*2024-2026 Clinical Science Fellow
The Ohio State University College of Pharmacy*

EXPERIENCE

Succeeding in the biopharma industry entails more than possessing scientific expertise — it requires proficiency in collaborative team-work, effective communication and an aptitude for adapting to new and evolving industry trends.

Engage in comprehensive hands-on experience

Work alongside industry experts and thought leaders

Apply the skills acquired during pharmacy school training

Preceptors and mentors provide a supportive learning environment

Acquire a competitive edge in the pharmaceutical industry

RPIF & Daiichi Sankyo Fellowship Alumni

* Current Full-Time Employee at Daiichi Sankyo

Christina N. Breen, Pharm.D.
Medical Affairs (2001-2002)

Amy Desai, Pharm.D.
Medical Affairs (2002-2003)

Christine L. Racchini, Pharm.D.
Scientific Affairs (2002-2003)

Brad F. Tumminello, Pharm.D.
Medical Affairs (2003-2004)

Gina L. Vestea, Pharm.D.
Scientific Affairs (2003-2004)

Giby Thomas, Pharm.D.
Medical Affairs (2004-2005)

Mahesh Tawney, Pharm.D.
Scientific Affairs (2004-2005)

Theresa D. Ankamah, Pharm.D.
Medical Affairs (2005-2006)

Nana K. Wiafe-Ababio, Pharm.D.
Scientific Affairs (2005-2006)

Jessa Ford Depew, Pharm.D.
Medical Affairs (2006-2007)

Chhaya Patel, Pharm.D.
Medical Affairs (2006-2007)

BoYoung Goh, Pharm.D.
Medical Affairs (2007-2008)

Jalpa Patel, Pharm.D.
Medical Affairs (2007-2008)

Matthew Wong, Pharm.D.
Medical Affairs (2008-2009)

Nisha Patel, Pharm.D.
Medical Affairs (2008-2009)

Neil Mattai, Pharm.D.
New Product Market Research
(2008-2009)

Dominic Lai, Pharm.D.
Medical Affairs (2009-2010)

Maninee Patel, Pharm.D.
Medical Affairs (2009-2010)

Irene Wang, Pharm.D.
Medical Affairs (2010-2011)

Dipam Doshi, Pharm.D.
Medical Affairs (2010-2011)

Ashley S. Johnson, Pharm.D.
Medical Affairs (2010-2011)

Michelle Lee, Pharm.D.
Medical Affairs (2011-2012)

Ame Patel, Pharm.D.
Medical Affairs (2011-2012)

Nupur Patel, Pharm.D.
Medical Affairs (2011-2012)

Ruth Haile-Meskale, Pharm.D., M.B.A.
Medical Affairs (2012-2013)

Eric Zhao, Pharm.D.
Medical Affairs (2012-2013)

Monica Sukhatme, Pharm.D.
New Product Business Analytics
(2011-2013)

* Poonam Fredeman, Pharm.D.
Medical Affairs (2012-2014)

Jacob Reichert, Pharm.D.
Medical Affairs (2013-2015)

Chrissie Chew, Pharm.D.
Medical Affairs (2013-2015)

Benjit Singh, Pharm.D.
Commercial, New Product Planning
(2013-2015)

* Sarah Kwon, Pharm.D., M.B.A.
Marketing Sciences (2013-2015)

Nilomi Shah, Pharm.D.
Medical Affairs (2014-2016)

Alexander Oladele, Pharm.D., R.Ph.
Medical Affairs (2015-2017)

Gediminas Pliura, Pharm.D., R.Ph.
Commercial, New Product Planning
(2015-2017)

Bridget McGugan, Pharm.D., M.B.A.
Commercial, Market Research
Oncology (2016-2018)

Alyson Sapirstein, Pharm.D.,
R.Ph., M.B.A.
Commercial, Global Oncology
Marketing (2017-2019)

* Bridgette LeClair, Pharm.D., R.Ph.
U.S. Medical Affairs (2017-2019)

* Lukasz Jarosz, Pharm.D.
Global Business Development –
Transactions (2018-2020)

Joshua Lin, Pharm.D., R.Ph.
U.S. Medical Affairs (2018-2020)

Harsh Reddy, Pharm.D., R.Ph.
Global Oncology Marketing (2018-2020)

Omama Zubairi, Pharm.D.
Global Medical Affairs, Oncology
(2018-2020)

* Samantha Breckenridge-Vesper, Pharm.D.
U.S. Medical Affairs (2019-2021)

Haeyon Lee, Pharm.D.
U.S. Medical Affairs (2019–2021)

Rohan Chittella, Pharm.D.
Commercial (2019-2021)

Nikhil Dondapati, Pharm.D.
Commercial (2019-2021)

* Mackenzie Henderson, Pharm.D., R.Ph.
Pharmacoepidemiology (2019–2021)

Alexander Huelsman, Pharm.D., R.Ph.
U.S. Medical Affairs (2020-2022)

* Joseph Cheng, Pharm.D.
U.S. Medical Affairs (2020-2022)

Alberta Drake, Pharm.D., R.Ph.
Global Oncology Market Research
(2020-2022)

* Jill Desai, Pharm.D., R.Ph.
Global Oncology Market Research
& Insights (2020-2022)

* Eric Wang, Pharm.D.
Pharmacoepidemiology (2020-2022)

* Cindy Li, Pharm.D.
Clinical Development (2020-2022)

Elizabeth Booth, Pharm.D., R.Ph.
QCP (2020-2022)

* Andrew Perez-Viñas, Pharm.D., M.B.A.
U.S. Medical Affairs (2021-2023)

* Brigitte Azzi, Pharm.D.
U.S. Medical Affairs (2021-2023)

* Morgan Bowling, Pharm.D.
Global Oncology Medical Affairs
(2021-2023)

Samantha Wilusz, Pharm.D.
Global Oncology Medical Affairs
(2021-2023)

* Michael Obineme, Pharm.D., R.Ph.
Global Business Strategy & Analytics
(2021-2023)

* Gregory Waldek, Pharm.D., R.Ph.
Global Business Strategy & Analytics
(2021-2023)

* Mohamed Kashkoush, Pharm.D., R.Ph.
Global Business Development
(2021-2023)

* Priyanka Yalamanchili, Pharm.D., R.Ph.
Pharmacoepidemiology (2021-2023)

* Aaron Tocker, Pharm.D.
Clinical Science (2021-2023)

Thi Nguyen, Pharm.D., R.Ph.
Clinical Science (2021-2023)

* Brittany Tran, Pharm.D.
QCP (2021-2023)

* Youngjun Yoo, Pharm.D., R.Ph.
QCP (2021-2023)

Timothy Hajj Jr. Pharm.D.
Global Regulatory Affairs (2021-2023)

Rohan Vashi, Pharm.D.
Global HEOR (2021-2023)

* Jessica Adams, Pharm.D.
Clinical Science (2022-2024)

* Anna Wise, Pharm.D.
Clinical Science (2022-2024)

* Anthony Mack, Pharm.D.
Clinical Science (2022-2024)

* Lindsay Ratner, Pharm.D.
Companion Diagnostics (2022-2024)

* Jenna Park, Pharm.D.
Companion Diagnostics (2022-2024)

* Kaide Udit, Pharm.D.
Global Clinical Operations
(2022-2024)

* Eliana Maia-Goldstein, Pharm.D.
QCP (2022-2024)

* Alexander Yu, Pharm.D.
QCP (2022-2024)

* Pooja Vekaria, Pharm.D.
Regulatory Affairs (2022-2024)

Shafat Selim, Pharm.D.
Business Strategy & Analytics
(2022-2024)

Madison Henry, Pharm.D.
Global Oncology Medical Affairs
(2022-2024)

* Kyle Taylor, Pharm.D.
Global Oncology Medical Affairs
(2022-2024)

* Nikhil Mohan, Pharm.D.
U.S. Medical Affairs (2022-2024)

* Thanh Mai, Pharm.D.
U.S. Medical Affairs (2022-2024)

* Timothy Choi, Pharm.D.
CSPV (2022-2024)

* Chaeyun Lee, Pharm.D.
CSPV (2022-2024)

* Oluwatosin Fofah, Pharm.D.
Pharmacoepidemiology
(2022-2024)

* Amira Geris, Pharm.D.
Clinical Science (2023-2025)

* Chinh Kieu, Pharm.D.
Clinical Science (2023-2025)

* Yash Patel, Pharm.D.
Clinical Science (2023-2025)

* Elizabeth Barton, Pharm.D.
Clinical Science (2023-2025)

* Chloe Koo, Pharm.D.
QCP (2023-2025)

* Jahmal Williams, Pharm.D.
Global Oncology Medical Affairs
(2023-2025)

* Claire Groce, Pharm.D.
Global Oncology Medical Affairs
(2023-2025)

* Starr Vang, Pharm.D.
Global Clinical Operations & Planning
(2023-2025)

* Candice Drinkwater, Pharm.D.
Pharmacoepidemiology (2023-2025)

* Alyssa Dempsey, Pharm.D.
U.S. Medical Affairs (2023-2025)

* Yoo Meen Suh, Pharm.D.
U.S. Medical Affairs - MI&E
(2023-2025)

* Ryan Friedrich, Pharm.D.
Business Strategy & Analytics
(2023-2025)

* Joon Lee, Pharm.D.
Global Business Development
(2023-2025)

* Mu Qiu, Pharm.D.
Business Strategy & Analytics
(2023-2025)

* Sheena Licata, Pharm.D.
U.S. Marketing (2023-2025)

* Kajal Rana, Pharm.D.
U.S. Marketing (2023-2025)

* Juhi Hegde, Pharm.D.
CSPV (2023-2025)

Simrun Lakhani, Pharm.D.
CSPV (2023-2025)

Khushbu Patel, Pharm.D.
Global Oncology Value, Access
& Pricing (2023-2025)

Sarah Park, Pharm.D.
Global HEOR (2023-2025)

* Libby Shelton, Pharm.D.
U.S. Training & Development
(2023-2025)

Sarayu Anmangandla, Pharm.D.
Translational Science (2023-2025)

* Victor Gazdoui, Pharm.D.
Companion Diagnostics
(2023-2025)

* Eileen Zheng, Pharm.D.
Clinical Science (2024-2026)

* Jatin Jain, Pharm.D., R.Ph.
Clinical Science (2024-2026)

* Jacqueline Conti, Pharm.D., R.Ph.
Clinical Science (2024-2026)

* April Zhou, Pharm.D.
QCP (2024-2026)

Elise Vo, Pharm.D.
QCP (2024-2026)

* Sophia Ventrano, Pharm.D.
Translational Science (2024-2026)

* Sara McGowen, Pharm.D., R.Ph.
Global Regulatory Affairs (2024-2026)

Anh Huynh, Pharm.D., M.S.P.S.
Companion Diagnostics (2024-2026)

* Caroline Culpepper, Pharm.D., R.Ph.
Commercial BD (2024-2026)

Rachel Clark, Pharm.D., R.Ph.
Pharmacoepidemiology (2024-2026)

* Matthew Armanus, Pharm.D., R.Ph.
U.S. Medical Affairs (2024-2026)

* Ethan Lim, Pharm.D.
U.S. Medical Affairs (2024-2026)

* Shadi Dahduli, Pharm.D., R.Ph.
Global Oncology Marketing
(2024-2026)

* Aryanna Ilamni, Pharm.D.
U.S. Marketing (2024-2026)

* Sabrina Wang, Pharm.D., R.Ph.
Global HEOR (2024-2026)

Amanda Lin, Pharm.D., R.Ph.
U.S. Training & Development
(2024-2026)

* Chyan Decker, Pharm.D.
Global Oncology Medical Affairs
(2024-2026)

* Sophie Wei, Pharm.D., R.Ph.
Global Oncology Medical Affairs
(2024-2026)

Our Leadership Team

is the heart of our program's success. By fostering meaningful partnerships across committees and aligning around a shared vision, they shape the culture, strengthen the fellow experience, and help cultivate the next generation of industry leaders.



STANDING (L TO R): Peter Gordinier (GRA), Kimberly Small (Fellowship Director), Andrew Phan (CS), John Rizk (USMA)
SITTING (L TO R): Dev Patel (GCSPV), Sinduja Sivakumar (GOMA), Carsyn Norway (Global Oncology HEOR & RWE), Rayshion Nezy (GCSPV)

The Steering Committee

will contribute to program strategy and direction with the goals of **fostering** professional and personal growth, **engaging** all stakeholders, and **retaining** the developed talent.

FELLOWSHIP DIRECTOR



Kimberly Small
Associate Director, Early Career Talent Programs
HUMAN RESOURCES

EXECUTIVE SPONSORS



Tamy Recchia, Pharm.D.
*Executive Director,
USMA Innovation
and Excellence*
U.S. MEDICAL AFFAIRS



Dalal Nesheiwat, Pharm.D.
*Vice President,
Head of R&D
Operations*
R&D

CO-CHIEF FELLOWS



**Sinduja Sivakumar,
Pharm.D., R.Ph.**
Second-Year Fellow
**GLOBAL ONCOLOGY
MEDICAL AFFAIRS**



John Rizk, Pharm.D.
Second-Year Fellow
**U.S. MEDICAL
AFFAIRS**

COMMITTEE MEMBERS



Kristin Vaneekhoven, Pharm.D.
*Senior Director, Head of Oncology
Global Medical Content & Training*
GLOBAL ONCOLOGY MEDICAL AFFAIRS



**Morgan Bowling,
Pharm.D.**
*Associate Director,
U.S. Medical Affairs*
U.S. MEDICAL AFFAIRS



Jill Desai, Pharm.D.
*Associate Director,
Global Brand Strategy*
U.S. MARKETING



**Mackenzie Henderson,
Pharm.D.**
*Associate Director,
Pharmacoepidemiology*
PHARMACOEPIDEMIOLOGY



**Kendall Sullivan,
Pharm.D.**
*Director,
Clinical Science*
CLINICAL SCIENCE



AS CO-CHIEF FELLOWS, WE...

work with the Fellowship Steering Committee (FSC) to drive program strategy and implement deliverables that enhance fellows' personal and professional development. We also serve as the point of contact between RPIF leadership and Daiichi Sankyo fellows, liaise between the FSC and fellows, support the committee leads, and lead bi-weekly fellowship meetings.

**Sinduja Sivakumar,
Pharm.D., R.Ph.**

Global Oncology Medical Affairs

**John Rizk,
Pharm.D.**

U.S. Medical Affairs

Fellowship Committee Leads

MARKETING



**Carsyn Norway,
Pharm.D.**

Oversees the development of the Daiichi Sankyo Pharm.D. Fellowship Program recruitment brochure aligned with RPIF, coordinates annual Fellowship Showcase Day and executes marketing and social media strategy across internal and external platforms



RECRUITMENT



**Peter Gordinier,
Pharm.D., R.Ph.**

Develops RPIF / Daiichi Sankyo recruitment strategy while guiding fellows and stakeholders throughout recruitment, including structuring candidate interviews, on-site touch points and ASHP Midyear



ALUMNI RELATIONS



**Rayshion Nezy,
Pharm.D.**

Heads early efforts to build the Pharm.D. fellow alumni community at Daiichi Sankyo and promote engagement with the company's fellowship program through hosting Lunch & Learns, workshops, guest speaker events and other networking activities



EXTERNAL ENGAGEMENT



**Dev Patel,
Pharm.D., R.Ph.**

Coordinates externally facing Daiichi Sankyo fellowship events, including participation in RPIF FIND and Daiichi Sankyo's Fellowship Receptions



FELLOW ENGAGEMENT



**Andrew Phan,
Pharm.D.**

Plans internal activities for fellows with the purpose of developing strong interprofessional relationships and promoting a positive, strong company culture





Recruiting FELLOWSHIPS

- Clinical Science (CS): *Three, 2-Year Positions* 17
- Global Oncology Medical Affairs (GOMA): *One, 2-Year Position* 23
- Global Regulatory Affairs (GRA): *One, 2-Year Position*..... 27
- U.S. Marketing Fellowship (USM): *One, 2-Year Position* 31
- U.S. Medical Affairs (USMA) Oncology: *One, 2-Year Position* 35
- U.S. Training & Development: *One, 2-Year Position* 39

Clinical Science (CS) Fellowship

One, 2-Year Early Development Oncology (EDO) Position

One, 2-Year Late-Stage Oncology Clinical Development Position

One, 2-Year Protocol Development Capability Position

The Clinical Science Fellowship Program offers the opportunity for fellows to learn about how an oncology product moves through different stages of clinical development in its life cycle. This experience offered at Daiichi Sankyo provides fellows with hands-on experience of learning about and contributing to clinical trials of cutting-edge compounds in the oncology therapeutic area.

The aim of the fellowship is to provide the necessary tools for the fellow to be able to design and manage clinical trials, provide input to the strategic decisions that optimize the study conduct, and lead tactics that support individual clinical trials and the program as a whole. Fellows will have close collaboration with other functional areas such as Clinical Operations, Project Management, Regulatory Affairs, and many other groups at Daiichi Sankyo.

CS Fellowship Interactions & Expectations

Interactions

In addition to oncology researchers and third party investigators, it is expected that fellows will interact with other functions particularly:

- Physician Scientists
- Clinical Operations
- Medical Affairs
- Companion Diagnostics
- Clinical Safety
- Data Management
- Project Management
- Regulatory Affairs
- Biostatistics
- Commercial
- Clinical Pharmacology
- Translational Science

Requirements

It is expected that fellows will have:

- Analytical and organizational skills
- Oral and written communication skills
- Scientific writing skills
- Ability to work independently and collaboratively with a team
- Leadership and delegation skills
- High ethical behavior and integrity

The Daiichi Sankyo Clinical Science Fellowship is positioned to provide hands-on oncology clinical trial experience, supported by a strong mentorship and alumni network that accelerates professional growth and career success.

CS Fellowship Activities & Experiences

Responsibilities

The main responsibilities of the Clinical Science fellow in Early Development Oncology include:

- Assist shaping Clinical Development Plan (CDP) by evaluating Phase I data, competitive intelligence, regulatory trends, and emerging scientific evidence to inform early strategic direction
- Engage Phase I investigators to design and execute signal-seeking and proof-of-concept studies that expand the company's portfolio beyond DXd-ADC programs
- Monitor early-phase clinical trials to ensure patient safety, identify emerging efficacy signals, and support timely go/no-go decisions for transition into late-stage development
- Support clinical trial planning and execution by contributing to protocol and informed-consent development, electronic data capture design, and alignment with global health authorities
- Prepare scientific materials for internal governance, external collaborations, and peer-reviewed publications
- Drive cross-functional collaboration across clinical study teams (e.g., clinical operations, biostatistics) and broader scientific partners (e.g., preclinical/translational researchers) to advance programs with integrated expertise

The main responsibilities of the Clinical Science fellow in Late-Stage Oncology Clinical Development include:

- Assist and/or lead the clinical study team in protocol and informed consent form (ICF) writing, as well as amendments
- Conduct literature searches with the support of AI to inform clinical decisions on study-level and program-level work
- Critically review study data on an ongoing basis through utilization of various data review tools available
- Interact with vendors that support the clinical trials and ensure timely delivery of work
- Contribute to project- and department-level work for the Clinical Science Department
- Engage Key External Experts (KEEs) and Principal Investigators in site initiation visits, investigator meetings, and conferences
- Assist and/or lead efforts in the development and presentation of scientific material and trainings intended for internal and/or external stakeholders
- Engage in strategic discussions regarding study design based on evolving competitive and regulatory landscape
- Liaise with various advisory committees such as Scientific Steering Committees or Data Monitoring Committees
- Contribute to the annual preparation and updates of key regulatory documents, including the Investigator's Brochure and Development Safety Update Report
- Provide clinical review and feedback pertaining to relevant study documents such as case report forms, data management plans, pharmacy manuals, and statistical analysis plans

The main responsibilities of the Clinical Science fellow in Protocol Development Capability include:

- Contribute to protocol and ICF development across early- and late-stage oncology studies
- Build a strong understanding of how clinical protocols are structured as a core clinical scientist competency, using contemporary approaches that support clarity, consistency, and regulatory alignment across the study life cycle
- Develop foundational knowledge of how scientific rationale—including tumor biology, mechanism of action, and biomarker strategy—is translated into study design elements such as objectives, endpoints, and eligibility criteria
- Assist and/or lead the evolution of protocols over time, including amendments, and how study-level decisions contribute to broader clinical development strategy and key decision points
- Contribute to protocols that integrate input from clinical operations, biostatistics, regulatory, safety, and translational science teams
- Build, transform, and refine modern, structured global protocols that advance how protocols are developed — enabling greater clarity, consistency, efficiency, and cross-functional alignment across the study life cycle
- Provide clinical review and feedback pertaining to relevant study documents such as case report forms, data management plans, pharmacy manuals, and statistical analysis plans

Why did you select the Daiichi Sankyo CS Fellowship Program?

CS Current Fellow PERSPECTIVES



- Supported with exceptional opportunities and experiences
- Strong oncology pipeline to address unmet medical needs
- Meaningful employee core values reflected on patients world-wide

Engy Dous, Pharm.D., R.Ph.

*Second-Year Fellow,
Clinical Science
Long Island University,
Arnold & Marie Schwartz
College of Pharmacy*



- Commitment to transforming oncology treatment landscape
- Collaborative environment focused on advancing innovative therapeutics
- Dedication to sustainability and global health

Maya Patel, Pharm.D., R.Ph.

*Second-Year Fellow,
Clinical Science
University of Florida
College of Pharmacy*



- Emphasis on leadership development
- Expanding and innovative oncology pipeline
- Meaningful and patient-centric company values

Andrew Phan, Pharm.D.

*Second-Year Fellow,
Clinical Science
University of the Pacific,
Thomas J. Long School of Pharmacy*



- People-first culture centered on mentorship and collaboration
- Innovative and expanding ADC pipeline at the forefront of oncology
- Opportunity to contribute to groundbreaking science with direct patient impact

Jennifer Nakhla, Pharm.D.

*First-Year Fellow,
Clinical Science
Rutgers University,
Ernest Mario School of Pharmacy*

The Daiichi Sankyo CS Fellowship Program provides fellows with...

CS Fellowship Leadership Insights



Experience across functions
in an innovative global
healthcare company

Opportunity to support
development of novel
therapeutics for patients

Large network of fellows and
opportunity to build network
with other professionals

Experienced mentors and
cross-functional leaders
in the pharmaceutical industry

Collaborative, forward-thinking
environment that is shaping
the future of oncology

Stephen Letrent,
Pharm.D., Ph.D., M.B.A.

Vice President, Global Head Clinical Science



Experiences in early oncology development,
including Phase I/II trial execution, KEE
engagement, and CDP strategy development

Strong understanding of tumor biology,
mechanism-of-action rationale, and biomarker
strategies for emerging therapeutic modalities

Insight into how early-stage data informs
go/no-go decisions, portfolio prioritization,
and long-term clinical development planning
in a competitive oncology landscape

Broad network of fellows, experienced
mentors and cross-functional leaders
in the pharmaceutical industry

Contributions as a team member in the
newly established Daiichi Sankyo Early
Oncology Development function, supporting
workstreams and helping shape its culture

Michele Sharr, Ph.D.

Head of Early Clinical Science & Operations

A Daiichi Sankyo CS Fellow can expect...

CS Fellowship Leadership Insights



Hands-on experience in the clinical development process across early- and late-stage oncology studies

Broad cross-functional collaboration with clinical operations, biostatistics, regulatory, safety, and translational science teams

Opportunity to meaningfully contribute as part of the clinical study team supporting scientific decision-making

Accelerated career development through structured mentorship and training

Foundational knowledge of comprehensive clinical study design elements

Maria Bowen

*Head of Protocol Excellence,
Clinical Science | Preceptor*



Hands-on proficiency in oncology clinical development through Phase I/II trials, with transferable skills applicable to late-stage programs

Experience in broad cross-functional collaboration with clinical operations, biostatistics, regulatory, pharmacovigilance, and preclinical/translational research teams


Foundational knowledge and skills in early-phase clinical trial design and execution to support downstream late-stage development planning

Cutting-edge science, evidence generation processes, and close collaboration with leading global investigators

Accelerated career growth through structured mentorship and training programs at Daiichi Sankyo, extending beyond early clinical development

Satoshi Nishioka, Ph.D., MSc

*Director, Clinical Science,
Early Development Oncology | Preceptor*



Valuable, hands-on experience in running global Phase II and/or Phase III oncology clinical trials that can inform dose optimization decisions and lead to or support regulatory submissions

To be a key contributor to the study team and ability to work cross-functionally with other key stakeholders including Physician Scientists, Clinical Operations, Biostatistics and Data Management, Clinical Safety and Pharmacovigilance, and Regulatory Affairs

To play a leading role in executing key study activities and deliverables from study start-up through study close-out to achieve critical milestones

To develop expertise in how to design and execute clinical studies at a high level, critically evaluate data and how this impacts the current study and broader clinical development program, as well as contribute to study- and program-level strategic discussions

Joseph Pariseau, Pharm.D.

*Director, Clinical Science,
Late Stage Oncology | Preceptor*

Global Oncology Medical Affairs (GOMA) Fellowship

One, 2-Year Position

GOMA's mission is to transform the scientific evidence of the broad and innovative Daiichi Sankyo oncology portfolio to locally relevant clinical practice in all countries across the world. GOMA delivers high quality scientific and medical information and publications needed to educate and support healthcare professionals' treatment decisions, informing local and global treatment guidelines. GOMA supports our Research and Development colleagues by identifying evidence for potential new indications and sub-populations of interest. GOMA supports access submission efforts and educates patient organizations on the burden of the disease and its treatment options.

The goal of the program is to introduce the fellow to the breadth and depth of different GOMA activities and to gain hands-on experience working on deliverables.

Over the two years, the fellow will gain broad exposure to different activities through rotation in four out of five areas within GOMA (approximately six months each). The fellow will work under the guidance of the respective function to gain experience delivering against the Medical Affairs plan and participate in strategic planning in:

- Publications
- Clinical Operations
- Medical Strategy/Evidence Generation
- External Scientific Collaboration
- Medical Content & Training

The GOMA Leadership Team will match the available areas for year one and year two fellows with their interest and with an availability of a suitable project. This will allow the fellow to work on a project from its conception to the final delivery with support from a GOMA director who is responsible for day-to-day operations of the respective area.

FELLOWS

GOMA Fellowship Activities & Experiences

Responsibilities

The key responsibilities and projects vary depending on the GOMA area and include:

Publications

- Preparing and submitting a manuscript to a scientific journal
- Preparing and submitting an abstract to a global congress
- Preparing a poster or slides for an oral presentation for disclosure at a global congress

Clinical Operations

- Developing and executing interventional Phase IIIb/IV and non-interventional studies, medical access programs, and externally sponsored research
- Assisting with governance committees, drug supply management, sponsor oversight, and quality management

Medical Strategy/Evidence Generation

- Assisting GOMA Team Lead with assessment of evidence gaps and unmet medical needs
- Planning activities to address the identified gaps
- Assisting in building Global Brand Plans: Situation Analysis, Strategic Imperatives and developing plans for medical affairs activities

External Scientific Collaboration

- Planning, delivering and summarizing outcomes of an external advisory board (Medical Experts and/or Patient Advocacy Group Representatives)
- Coordinating KEE engagements at congresses
- Generating global insights reports
- Engaging with patient advocacy organizations, integrating the patient voice, and improving patient access/knowledge

Medical Content & Training

- Crafting diverse types of medical affairs content designed to educate the healthcare community
- Developing educational materials and training events for training internal medical teams on our science for engagement readiness
- Preparing medical booth content for display at global congress booths
- Exposure to medical review of global promotional materials, Global Medical Information inquiry handling, and data on file request handling

Interactions

GOMA interacts on a daily basis with multiple internal and external stakeholders.

Key internal partner functions include:

- Regional Medical Affairs
- Global Research and Development
- Global Marketing
- Global Market Access and Pricing
- Global Clinical Safety and Pharmacovigilance
- Legal
- Regulatory Affairs
- Corporate Communications

Key external partners include:

- Global Key External Experts
- Healthcare Professionals (physicians, nurses, pharmacists)
- Patient Advocacy Groups representing patients in different countries and regions of the world
- Health Authorities (FDA, CHMP/ EMA, PMDA)
- Medical Societies (ASCO, ESMO, ASH, EHA)

During the participation in the program, the fellow will be encouraged and expected to participate in all interactions with internal and external GOMA stakeholders alongside the other GOMA Team members.

Requirements

It is expected that the fellow will have:

- An interest in oncology through participation in prior research projects, internships, clinical rotations, etc.
- A scientific curiosity and willingness to navigate the complexities of oncology drug development from early clinical stages to launch in different countries around the world
- Ability to synthesize their knowledge and present in a clear and concise manner when interacting on a daily basis with different GOMA stakeholders

Why did you select the Daiichi Sankyo GOMA Fellowship Program?

GOMA Current Fellow PERSPECTIVES



- Focused on advancing patient-centric solutions
- Collaborative environment supports innovative and robust oncology pipeline
- Strong emphasis on maximizing opportunities and visibility for fellows

**Sinduja Sivakumar,
Pharm.D., R.Ph.**

*Second-Year Fellow,
Global Oncology Medical Affairs
Rutgers University,
Ernest Mario School of Pharmacy*



- Steadfast investment in the personal and professional development of fellows
- Integrity-driven leadership that keeps patients at forefront of oncology care
- Impactful collaboration that drives worldwide oncology excellence

**Stacey Velasco,
Pharm.D., M.B.A.**

*Second-Year Fellow,
Global Oncology Medical Affairs
Temple University School of Pharmacy*



- Mentorship that supports meaningful project ownership
- Opportunity to develop strong medical affairs and cross-functional skills
- Experience communicating cutting edge science in global oncology

**Lahar Miriyapalli,
Pharm.D.**

*First-Year Fellow,
Global Oncology Medical Affairs
University of Connecticut
School of Pharmacy*



- Global impact in oncology and strong innovation in patient-centered care
- Supportive company culture centered on meaningful connections
- Collaborative rotations with exposure, visibility, and growth opportunities

**Stacey Zhang,
Pharm.D.**

*First-Year Fellow,
Global Oncology Medical Affairs
Rutgers University,
Ernest Mario School of Pharmacy*

The Daiichi Sankyo GOMA Fellowship Program provides fellows with...



GOMA Fellowship Leadership Insights



Consistent fellow success
in pharmaceutical industry

Exposure to various
functional areas


Opportunities for cross-
departmental contributions

Diversified industry experience

Enhanced professional
development through
rotational training

**Thomas Malieckal,
Pharm.D., R.Ph.**

*Vice President, Medical Capabilities,
Global Oncology Medical Affairs |
Preceptor*



Industry-leading fellowship
program focused on
medical affairs careers

Strategic positioning for success
in the biopharmaceutical industry


Diverse rotational experiences
across key medical affairs
functions

Strong foundation in core
competencies

Tailored rotations based on
individual professional interests

**Donato S. Forlenza,
Pharm.D., R.Ph.**

*Associate Director,
Medical Content & Training Lead,
Global Oncology Medical Affairs*



Unique opportunity to gain
broad medical affairs exposure

Hands-on experience in
publications, medical content/
training, scientific engagement,
strategy, and patient advocacy

Strong foundation for a
successful medical affairs career

Continued growth through learning
from colleagues and mentors

Foundation for fellows to grow
into future medical affairs leaders

**Andrew L. Felicio,
Pharm.D., R.Ph.**

*Director, Publications,
Global Oncology Medical Affairs*

Global Regulatory Affairs (GRA) Fellowship

One, 2-Year Position

The Global Regulatory Affairs R&D Fellowship Program offers the opportunity to acquire first-hand working knowledge of the regulatory requirements for global drug development and the conduct of clinical studies. Using this knowledge, the fellowship also offers the opportunity to develop the necessary skill set to provide scientifically driven, tactical and strategic regulatory guidance to cross-functional project teams. Included within the Daiichi Sankyo oncology franchise are the cutting-edge antibody drug conjugate (ADC) compounds being developed using unique approaches to address the unmet medical needs of patients.

During this two-year program, the fellow will collaborate closely with colleagues and scientists representing diverse backgrounds, knowledge, and expertise, both within regulatory and across other functions (e.g., Clinical Development, Clinical Pharmacology, Biostatistics, Drug Safety, Translational Medicine, and Marketing).

The program also provides exposure to additional Regulatory Affairs subfunctions, including Regulatory Advertising & Promotion and Regulatory Intelligence & Policy, supporting a broader understanding of the evolving regulatory landscape and the diverse career opportunities within Regulatory Affairs.

GRA Fellowship Activities & Experiences

Responsibilities

Year One Responsibilities May Include:

- Develop an understanding of the drug development process and regulatory requirements to file and maintain Investigational New Drug Applications (IND), New Drug Applications (NDA) and Biologics License Applications (BLA)
- Participate in the development of global regulatory strategies and health authority interactions
- Prepare regulatory interaction documents and submission packages
- Acquire a working knowledge of international and country-specific requirements to support the conduct of global clinical studies
- Develop the necessary skill set to provide cross-functional project teams with rational and scientifically-driven regulatory strategic guidance across different phases of development
- Acquire a working knowledge of the regulatory requirements to support global drug approvals
- Attend an FDA meeting
- Collaborate cross-functionally with global colleagues in Japan, Europe and China, representing diverse backgrounds, knowledge, and expertise, including:
 - Regulatory-CMC (Chemistry, Manufacturing and Controls)
 - Regulatory Operations
 - Labeling
 - Clinical Development
 - Clinical Pharmacology
 - Biostatistics
 - Clinical Safety and Pharmacovigilance
 - Translational Medicine
 - Commercial

Year Two:

- Remain in Regulatory Affairs to expand your regulatory experience through exposure to other facets of drug development and health authority requirements

Requirements

It is expected that fellows will have:

- Sound scientific thinking
- Self-motivation
- Collaborative spirit
- Good written and oral communication skills

Why did you select the Daiichi Sankyo GRA Fellowship Program?



GRA Current Fellow PERSPECTIVES




- Passionate team focused on developing their fellows
- Opportunity to be involved in the research of impactful oncology medications
- Innovative and collaborative environment focused on patient-centered solutions

Peter Gordinier, Pharm.D., R.Ph.

*Second-Year Fellow,
Global Regulatory Affairs
University of Connecticut School of Pharmacy*

The Daiichi Sankyo GRA Fellowship Program provides fellows with...

GRA Fellowship Leadership Team



Meaningful exposure to the strategic and operational aspects of regulatory affairs across the drug development life cycle

Opportunity to work alongside experienced regulatory strategists and actively contribute to key regulatory activities such as FDA submissions and health authority interactions

Active participation as integral members of global regulatory teams working toward important development and regulatory milestones

Mili Khubani, Pharm.D., R.Ph.

Director, Regulatory Affairs | Preceptor



Hands-on learning and direct experience working side-by-side with seasoned drug developers

A unique environment of multi-cultural influences where you will play an integral part in global drug development

Amita Chaudhari, M.S.

Vice President, Head of North America Regulatory Affairs



U.S. Marketing (USM) Fellowship

One, 2-Year U.S. Marketing Position

U.S. Marketing is the engine that drives strategies and tactics to help get our medicines to patients in need. Fundamental to this fellowship will be working cross-functionally to support approved products and/or prepare for upcoming launches. The work will be in breast, lung, other solid tumors and hematology and support the success of the brand. The fellow will have the opportunity to participate in the launch planning and development of key resources and partner with a variety of stakeholders to ensure we execute with excellence and deliver for our patients.

U.S. Marketing Fellowship Activities & Experiences

Responsibilities

Fellows will receive one-on-one preceptor mentoring and a number of opportunities to undertake U.S. Marketing activities, including:

U.S. Marketing

- Work with cross-functional business partners on the development and execution of promotional resources
- Help develop personal and non-personal promotion tactics that support brand strategy and are executable by customer facing teams
- Present to various internal management committees and groups
- Help oversee various agency relationships
- Manage productive and timely communication with all external agency partners

Interactions

It is expected that fellows will interact with other functions including:

- Insights and Analytics
- U.S. Medical Affairs
- U.S. Market Access
- Finance
- Sales Training
- Marketing
- Sales
- Data Governance
- IT
- Alliance Partners (as applicable)

Requirements

It is expected that fellows will have:

- Critical thinking
- Creativity
- Highly motivated
- Intellectual curiosity
- Strong oral and written communication skills
- Organized and responsible
- Keen to work with individuals from diverse backgrounds

Why did you select the Daiichi Sankyo USM Fellowship Program?

U.S. Marketing Current Fellow PERSPECTIVES



- Leaders in the marketplace with innovative and science-driven therapies that are transforming care
- Marketing strategies that embrace evolving trends and reflect a deep commitment to patient care
- Culture that actively demonstrates its values through growth and development

Rohit Marwah, Pharm.D.

*Second-Year Fellow,
U.S. Omnichannel Marketing
University of Pittsburgh
School of Pharmacy*



- Seamless marketing driving brand growth through strategic initiatives
- Strong commitment to innovation and patient care
- Environment focused on growth and meaningful impact

Hanna Song, Pharm.D.

*Second-Year Fellow,
U.S. Omnichannel Marketing
St. John's University College of
Pharmacy and Health Sciences*



- Commitment to improving patient outcomes through scientific innovation
- Differentiated ADC technology platform and potential to transform the future of cancer treatment
- Unique blend of strategy, creativity, and cross-functional collaboration

Rhea Misra, Pharm.D.

*First-Year Fellow,
U.S. Marketing
University of California,
San Francisco School of Pharmacy*



- Emerging global leader in oncology committed to delivering practice-changing, patient-centered innovation
- Fully integrated marketing team that fosters involvement in brand strategy and launch planning
- Company culture of respect, flexibility, mentorship, and employee growth

John Michael, Pharm.D.

*First-Year Fellow,
U.S. Marketing
Rutgers University,
Ernest Mario School of Pharmacy*

The Daiichi Sankyo USM Fellowship Program provides fellows with...



USM Fellowship Leadership Insights



Integrated member of
designated U.S. Marketing team


Make direct contributions to
advancing U.S. Marketing projects

Two-year immersive
program designed to develop
practical marketing skills,
industry knowledge, and
strategic thinking

Builds a strong foundation
for a career in pharmaceutical
Marketing

Kara Reheis, M.B.A.

Vice President, U.S. Marketing



Opportunity to make a broad
patient impact across unmet
need hematology areas

Support ongoing indications
while contributing to strategic
planning for upcoming launches

Opportunity to engage in multiple
phases of product life cycle
from current market support
to future commercialization

Puja Shah, Pharm.D.

Senior Director, U.S. Marketing



Participate in launch planning and
development of key resources

Collaborate with diverse
stakeholders to ensure
successful execution

Help deliver innovative therapies
that address critical patient
needs in high unmet need areas

Elyse Almeida

Director, U.S. Marketing | Preceptor

U.S. Medical Affairs (USMA) Oncology Fellowship

One, 2-Year Position

The goal of the two-year USMA Oncology Fellowship Program is to provide real-world, hands-on experience in oncology across traditional functional areas of a medical affairs department.

The USMA leadership will work with the fellow to concentrate their time in a specific functional area based on personal interest, experience, and the business opportunities of the Company. The fellow will have the opportunity to work on projects across several functional areas within medical affairs.

Over the two-year fellowship, the fellow will gain broad exposure to different functions within the USMA department, including:

- Medical Research & Strategy
- Field Medical Affairs
- Medical Information and Education
- Medical Affairs Operations (Scientific Engagement, Medical Insights & Reporting)
- Health Economics and Outcomes Research

FELLOWS

USMA Oncology Fellowship Activities & Experiences

YEAR 1

Project based with an opportunity to rotate within other areas of USMA

Medical Research & Strategy

- Engage with Key External Experts (KEEs)
- Participate in medical strategy planning activities and support product life cycle
- Collaborate with Field Medical to gather and convey insights to broader team
- Assist in advisory board planning
- Lead congress planning & cross-functional coordination
- Support sales & field medical training
- Work with vendors on slide development & scientific communications
- Contribute to competitive intelligence monitoring and reporting



Medical Information & Education

- Create, update & review medical response documents
- Share key insights with cross-functional teams
- Participate in dossier and testimony development
- Strategically review literature to identify educational gaps
- Assist in strategic planning from a medical information perspective
- Support independent medical education initiatives
- Serve as scientific resource for promotional review



Medical Affairs Operations

- Support generation, synthesis, and alignment of medical insights across key stakeholders
- Liaise with cross-functional teams outside of USMA to understand key business insights and translate implications for USMA stakeholders
- Facilitate development and adoption of new technologies and support digital innovation initiatives
- Provide comprehensive reporting in collaboration with FMA and MR&S to track progress, measure impact, and support data-driven decision-making



Interactions

USMA interacts on a daily basis with multiple internal and external stakeholders.

Key internal partner functions include:

- Field Medical Affairs
- Health Economics & Outcomes Research
- Marketing
- Medical and Sales Training
- Global Medical Affairs
- Pricing & Access
- Clinical Operations
- Clinical Development
- Legal Affairs
- Public Affairs

YEAR 2

Concentrated within a functional area of interest

Areas of Focus

- Deepen expertise within a chosen functional area



Why did you select the Daiichi Sankyo USMA Oncology Fellowship Program?

USMA Oncology Current Fellow PERSPECTIVES



- Robust mentorship culture and meaningful oncology pipeline
- Opportunity to bridge clinical evidence with strategic impact
- Value the flexibility and depth of experience offered

John Rizk, Pharm.D.

*Second-Year Fellow,
U.S. Medical Affairs
D'Youville University School of Pharmacy*



- Patient-focused innovation and growing impact on oncology
- Blend of science, communication, and strategic collaboration
- Opportunity to translate clinical data into meaningful outcomes for patients and providers

Priyam Patel, Pharm.D.

*First-Year Fellow,
U.S. Medical Affairs
UNC Eshelman School of Pharmacy*

The Daiichi Sankyo USMA Oncology Fellowship Program provides fellows with...

USMA Oncology Fellowship Leadership Team



Well-established, respected
Medical Affairs Fellowship Program

Strong support from Medical
Affairs Leadership Team

Extensive network of fellowship
alumni across the organization

Leadership team guides each
fellow's development plan

Focus on personal growth
and professional progress

Coordinated support ensures
fellow success during
and beyond the program

Kaley Lugo, Pharm.D., M.B.A.

*Associate Director, Medical Review,
Medical Information & Education,
Oncology | Preceptor*



Unique opportunity to explore
various medical affairs functions

Collaboration with cross-functional
teams (Global Medical Affairs,
Marketing, Training)

Versatile program structure
supports broad skill development

Builds strong professional network

Prepares fellows for successful
careers in medical affairs

Bridgette Leclair, Pharm.D.

*Associate Director,
U.S. Medical Affairs | Preceptor*



U.S. Training & Development Fellowship

One, 2-Year Position

The U.S. Training & Development (T&D) Fellowship offers a unique opportunity for the Pharm.D. fellow to get diverse exposure across the entire Oncology Business Division (OBD). The T&D team consists of five teams, including Medical Affairs Training, Commercial Sales Training, Market Access Training, Operations and Leadership Development. These teams support the entire OBD, including medical affairs, sales, market access, marketing, and business operations, working collaboratively with the strategy counterparts to develop innovative trainings for all of the field teams. The department's mission is to deliver first-in-class training solutions and execute product imperatives to sustain a competitive advantage in the oncology marketplace. We're looking for an innovative, driven fellow to help us in our mission.

The aim of the U.S. T&D Fellowship Program is to provide Pharm.D. fellows with a range of experiences collaborating on a variety of OBD Training and Development deliverables. In Year One, fellows will have the opportunity to work broadly across the training teams to establish a strong foundation in training and determine the area of interest for their second year of fellowship. The fellow will work under the guidance of the respective rotational Preceptor in each area. During Year Two (Elective Year), the fellow will work with the Program Preceptor to develop an individual development plan focused on areas of their interest. As part of a learning culture, the team is always looking for ways to tailor the fellowship experience to meet the development goals of the fellow.

U.S. T&D Fellowship Activities & Experiences

Responsibilities

U.S. Training & Development Fellows will rotate through multiple roles in the department including Field Sales Training, Medical Affairs Training and Market Access Training with exposure to Leadership Development and Operations

Field Sales, Medical Affairs and Market Access Training Rotation

- Enhance understanding of the Learning & Development strategy and activities for the commercial, market access, and medical field-facing teams to include:
 - Cross-functional collaboration with internal partners (e.g., Marketing, Home Office Medical Affairs) to understand training opportunities and identify innovative training solutions for all aspects of training
 - Leverage clinical expertise in the development of training materials, including foundational modules, competitive marketplace events, and regional and national sales meeting workshop content

Rotation Agnostic

- Present at and lead trainings for the various field teams, including medical science liaisons, oncology territory managers, oncology clinical educators, and more
- Execute delivery of training solutions through various communication channels and events including virtual and live training events
- Support the development of annual training plans
- Attend various medical/scientific meetings and national sales meetings
- Cross-collaborate within all aspects of the OBD to identify leadership and skill development opportunities
- Learn business operation systems that help support OBD and customer-facing teams
- Support the facilitation of leadership development trainings

Interactions

In addition to the Training and Development Team, it is expected fellows will interact with other internal functions including:

Internal

- Global & U.S. Medical Affairs
- Global & U.S. Market Access
- Global & U.S. Marketing
- Legal & Medical Reviewers
- Field Medical Affairs
- Commercial Sales Force
- Corporate Communications
- Human Resources
- Corporate Leadership Development

External

- Agency Partners
- Alliance Partners

Depending on interest, fellows may also interact with the following external stakeholders:

- Healthcare Professionals
- Other Key External Experts
- Patients

Requirements

It is expected that fellows should possess the following skills:

- Organized and Dependable
- Strong oral and written communication skills
- Innovative Thinkers
- Ability to be flexible
- Highly Motivated
- Open and Approachable
- Self-Motivated
- Ability to work independently and collaboratively with others

Why did you select the Daiichi Sankyo U.S. T&D Fellowship Program?

U.S. T&D Current Fellow PERSPECTIVES



- Culture that prioritizes learning, growth, and mentorship
- Pipeline focused on advancing oncology
- Opportunities to contribute to cross-functional initiatives and partnerships

Sophia Edgecombe, Pharm.D., R.Ph.

*Second-Year Fellow,
U.S. Training & Development
University of Kentucky College of Pharmacy*



- Redefining the standard of care in oncology treatment
- Culture that emphasizes intentional collaboration and individual growth
- Commitment to mentorship and leadership development for future professionals

James Tong, Pharm.D., R.Ph.

*First-Year Fellow,
U.S. Training & Development
University of Oklahoma College of Pharmacy*

The Daiichi Sankyo U.S. T&D Fellowship Program provides fellows with...



OBD T&D Fellowship Leadership Insights



Engages fellows with clinical, operational, interpersonal, and commercialization experiences

Partners with diverse customers across multiple roles and responsibilities

Offers unique, varied work and development opportunities exclusive to the Training & Development Department

Develops high-potential associates for long-term growth and careers

Belief that extraordinary people, culture, and innovative therapies combine to benefit patients

Ryan Hansen

Executive Director,
OBD Training and Development



Fellowship offers rare chance to support DSI assets in multiple stages (study start, commercialization, and life cycle management)

Focus on training and development perspective throughout the asset journey

Learn how cross-functional teams collaborate to design impactful learning journeys

Personalized experience in the second year by selecting a focus area aligned with career goals

Energetic and innovative team culture with a passion for developing emerging talent

Samantha Breckenridge (Vesper), Pharm.D.

Associate Director,
USMA Training and Development | Preceptor



Non-Recruiting FELLOWSHIPS

- Companion Diagnostics (CDx) 43
- Global Business Development (GBD) Transactions & Marketing 44
- Global Clinical Safety & Pharmacovigilance (GCSPV) 45
- Global Oncology Health Economics & Outcomes Research (HEOR) & Real-World Evidence (RWE) .. 46
- Global Oncology Marketing (GOM)..... 47
- Global Oncology Pricing, Reimbursement & Access (PRA)..... 48
- Global Regulatory Labeling Strategy (GRLS) 49
- Quality Assurance Good Manufacturing Practices (QA GMP) 50
- Translational Science (TS) 51

Companion Diagnostics (CDx) Fellowship

The mission of the Companion Diagnostics (CDx) Department in Global Oncology R&D is to make Precision Medicine a reality for patients. Our teams lead the co-development of companion diagnostics tests in parallel with the corresponding drug and in close collaboration with our external in vitro diagnostic partners. These tests can identify patients most likely to benefit from our therapies, can identify those patients at risk for side effects and can monitor treatment responses.

Precision Medicine is a growing field, and it is an increasingly important enabler for bringing innovative therapies to our patients. The goal of the two-year fellowship is to provide the fellow with experience in creation and oversight of CDx development strategies and in participating in activities for regulatory submission, approval and launch of CDx tests with our drugs.

CDx Current Fellow PERSPECTIVE


- Leader in ADCs and personalized medicine
- Advancing precision oncology via companion diagnostics
- Empowering patient-centric solutions



Feifei Jia, Pharm.D., R.Ph.

*Second-Year Fellow,
Companion Diagnostics*

*St. John Fisher University,
Wegmans School of Pharmacy*



Global Business Development (GBD) Transactions & Marketing Fellowship

The Global Business Development Fellowship Program offers a unique opportunity for the fellow to gain valuable industry experience at a pharmaceutical company with a rich research history and a promising future of growth.

The core focus of the program will be on business development opportunities and marketing across therapeutic areas, with an emphasis on oncology.

This two-year program is designed to provide hands-on opportunities with the Transactions and Marketing teams, together with active coaching and mentoring. Our goal is to help provide the fellow with the tools necessary for highly successful business development and marketing careers in the pharmaceutical industry.

GBD Current Fellow PERSPECTIVE

- Recognized leader in the ADC space
- Pipeline reflects a clear focus on moving the needle in cancer therapies
- Commitment to professional growth through mentorship, leadership support, and access to high-impact opportunities
- GBD offers a dynamic space, bridging science and strategy to drive impactful deals



Alicia Ngo, Pharm.D.

*Second-Year Fellow,
Global Business Development*

*Purdue University
College of Pharmacy*

Global Clinical Safety & Pharmacovigilance (GCSPV) Fellowship

GCSPV's vision is to put patients first by leading proactive safety surveillance and risk management to ensure quality and compliance throughout product life cycles. This is in line with the Daiichi Sankyo mission to create innovative pharmaceuticals to address diverse medical needs.

The GCSPV Fellowship provides the fellow with a comprehensive clinical safety experience within the ADC franchise/new wave products in the oncology therapeutic area, to prepare the fellow for a career in clinical safety and pharmacovigilance. The fellow will be fully immersed in clinical safety aspects of product development activities, defining and performing safety monitoring and risk mitigation activities, communication plans to internal and external stakeholders, regulatory submissions, post-submission health authority queries, and post-marketing safety surveillance. The fellow will be closely collaborating with global and cross functional teams, such as Clinical Development and Regulatory Affairs. As part of this experience, the fellow will also have the opportunity to rotate through various departments at Daiichi Sankyo in the second year of the fellowship.

GCSPV Current Fellow PERSPECTIVES

- Established presence in ADC development that enables the involvement of complex and impactful safety surveillance
- Exceptional commitment and integrity towards upholding patient safety in safety surveillance and risk management strategies
- Structured experiences that strengthen leadership, communication, and decision-making in patient-centered care
- Continual effort to enrich fellows' experience in areas of interest and introduce diverse opportunities to gain insight into other areas of the pharmaceutical industry
- Strong company culture with emphasis on professional development, collaboration, and mentorship
- Opportunity to support and uphold patient safety through both safety surveillance and strategy



**Rayshion Nezy,
Pharm.D.**

*Second-Year Fellow,
Clinical Safety &
Pharmacovigilance*

*University of Arizona,
R. Ken Coit College
of Pharmacy*



**Dev Patel,
Pharm.D., R.Ph.**

*Second-Year Fellow,
Clinical Safety &
Pharmacovigilance*

*Rutgers University,
Ernest Mario
School of Pharmacy*



**Cindy Nguyen,
Pharm.D.**

*Second-Year Fellow,
Clinical Safety &
Pharmacovigilance*

*University of California,
San Francisco
School of Pharmacy*



**Andres Garcia,
Pharm.D.**

*First-Year Fellow,
Clinical Safety &
Pharmacovigilance*

*University at Buffalo
School of Pharmacy
and Pharmaceutical
Sciences*



**Angel Thomas,
Pharm.D.**

*Second-Year Fellow,
Clinical Safety &
Pharmacovigilance*

*Rutgers University,
Ernest Mario
School of Pharmacy*

Global Oncology Health Economics & Outcomes Research (HEOR) & Real-World Evidence (RWE) Fellowship

The Global Oncology HEOR & RWE team is integral to generating the evidence to demonstrate the value of the Daiichi Sankyo oncology portfolio across global healthcare systems. By leveraging health economics, outcomes research, and real-world data, the team supports evidence-driven decision-making to inform access, reimbursement, and clinical practice. The Global Oncology HEOR & RWE Fellowship provides a unique opportunity to build expertise in evidence generation and value demonstration within the pharmaceutical industry. Over the two-year program, fellows gain hands-on experience supporting the development of HEOR strategies across the product life cycle, from early evidence planning to post-launch real-world evidence initiatives.

Fellows will work closely with cross-functional teams to design and execute studies that quantify clinical, economic, and humanistic outcomes. This includes contributing to real-world data analyses, economic modeling, and evidence synthesis, as well as supporting dissemination through publications and stakeholder engagement.

HEOR & RWE Current Fellow PERSPECTIVE

- Strong global presence and cutting-edge oncology pipeline
- Meaningful contribution to HEOR & RWE research and projects
- Positive company culture to nurture professional development



Carsyn Norway, Pharm.D.

*Second-Year Fellow,
Global Oncology HEOR & RWE*

*Rutgers University,
Ernest Mario School of Pharmacy*



Global Oncology Marketing (GOM) Fellowship

The Global Oncology Marketing Fellowship Program offers a unique opportunity for the fellow to gain valuable industry experience at a pharmaceutical company with a rich research history and a promising future of growth. This two-year program is designed to provide a comprehensive overview supporting compounds across the full spectrum of product development, but with an emphasis on oncology products, allowing hands-on opportunities, active coaching, mentoring and business analytics skill building. Our goal is to help provide the fellow with the tools necessary for highly successful marketing and market research careers in the pharmaceutical industry.

The core focus of the program will be on the Daiichi Sankyo pipeline for marketing and market research in oncology.

GOM Current Fellow PERSPECTIVE

- Healthy and innovative work culture
- Global impact in oncology with commitment to improving patient outcomes worldwide
- Structured career development with mentorship and professional training opportunities for long-term growth



Rita Aoun, Pharm.D.

*First-Year Fellow,
Global Oncology Marketing
Lebanese American University
School of Pharmacy*

Global Oncology Pricing, Reimbursement & Access (PRA) Fellowship

The Global Oncology PRA team is responsible for leading, developing and continually enhancing our value propositions to ensure optimal pricing and reimbursement for Daiichi Sankyo oncology products. The Global Oncology PRA fellowship offers a unique opportunity to gain experience and exposure to pharmaceutical market access. The two-year global program will offer a comprehensive and hands-on experience of reimbursement and payer strategy, supporting both in line and pipeline oncology products. This fellowship will provide the opportunity to partner with internal and external stakeholders to ensure market access strategy and tactics are aligned and localized. Our objective is to develop a specialized skill set to excel in global pricing & access careers in the pharmaceutical industry.

Global Oncology PRA Current Fellow PERSPECTIVE

- Strong leadership in global market access for innovative oncology therapies
- Bridge clinical evidence, policy, and real-world market opportunities
- Build expertise in pricing, reimbursement, and HTA strategy



Bhumika Devnani, Pharm.D., R.Ph.

*Second-Year Fellow,
Global Oncology Pricing,
Reimbursement & Access*

*University of Wisconsin-Madison
School of Pharmacy*

Global Regulatory Labeling Strategy (GRLS) Fellowship

The GRLS Fellowship is a distinguished program designed to immerse fellows in the intricacies of global pharmaceutical labeling and regulatory affairs. It provides a unique opportunity to gain firsthand experience in developing and implementing labeling strategies that meet global regulatory requirements and support global drug development with a primary focus on the rapidly expanding therapeutic area of oncology.

The fellow will collaborate with cross-functional teams, including regulatory affairs, clinical development, pharmacovigilance, marketing, and other stakeholders to ensure that labeling accurately reflects the safety, efficacy, and non-safety sections of pharmaceutical products. The fellow will also have the unique opportunity to make significant contributions to the development of labeling on portfolio products. This program provides in-depth training on developing effective labeling strategies to navigate complex challenges while aligning with the diverse regulatory requirements of key global markets.

GRLS Current Fellow PERSPECTIVE

- Strong people-centered culture that empowers teams to work together toward improving patients' lives
- Innovative global company dedicated to pushing boundaries and becoming a leading force in oncology
- Opportunity to contribute to regulatory labeling strategies and support global drug development



Chabelli Rivero, Pharm.D.

*First-Year Fellow,
Global Regulatory Labeling Strategy*

*Nova Southeastern University
College of Pharmacy*

Quality Assurance Good Manufacturing Practices (QA GMP) Fellowship

The Daiichi Sankyo QA GMP Fellowship Program offers a unique opportunity for the fellow to gain valuable industry experience in the quality assurance department at a pharmaceutical company with a rich history and a promising future in the oncology therapeutic area. It will provide the fellow a holistic understanding about the delivery of high-quality medicines from development to commercial phases.

This two-year program is designed to provide a comprehensive overview of the quality assurance organization supporting both commercial and investigational medicinal products. The QA GMP fellow will have a unique opportunity for a blend of hands-on and supportive roles in the six groups comprising QA GMP namely Strategy, Compliance, Quality Management Systems, Pharma Product, External Supplier and Audit.

The aim of the QA GMP Fellowship is to provide an opportunity to learn the skills required for a successful career in the quality assurance department of a global pharmaceutical company by ensuring the application of good manufacturing practices to support the quality of Daiichi Sankyo products supplied globally to patients.

QA GMP Current Fellow PERSPECTIVE

- Commitment to patient safety by ensuring the highest standards of quality and compliance
- Expertise in complex supply chain dynamics for ADCs and innovative global pipeline
- Cultivation of professional growth through cross-functional & international collaboration



Eun Sik (John) Cho, Pharm.D., R.Ph.

*Second-Year Fellow,
Global Quality Assurance
Good Manufacturing Practices*

*Rutgers University,
Ernest Mario School of Pharmacy*



Translational Science (TS) Fellowship

The mission of TS is to define and implement translational strategies and state-of-the-art biomarker technology platforms to enable successful drug development. TS delivers key translational data that contributes to clinical development strategies (forward translation) and pre-clinical opportunities for new targets and combinations (reverse translation). Our objectives are to inform dose selection and regimen through assessment of pharmacodynamic biomarkers, characterize drug mechanism of action, identify optimal target populations, devise and test hypotheses for patient selection, resistance mechanisms and combination strategies, and identify candidate biomarkers for CDx development.

TS Current Fellow PERSPECTIVE

- Dedication to improving patient outcomes through innovative science
- Exciting opportunities to make meaningful contributions to oncology drug development
- Supportive culture that fosters professional growth and development



Rong Xin Liu, Pharm.D.

*Second-Year Fellow,
Translational Science Early Oncology*

*University of Kansas
School of Pharmacy*



R | **RUTGERS HEALTH** **Institute for Pharmaceutical Industry Fellowships**

Ernest Mario School of Pharmacy (EMSOP)
Rutgers, The State University of New Jersey



Rutgers Pharmaceutical Industry Fellowship (RPIF) Program


Ernest Mario School of Pharmacy (EMSOP)

Rutgers, The State University of New Jersey


The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and is supported by a team of RPIF alumni experienced in the pharmaceutical industry.



Joseph A. Barone,
PharmD, FCCP
*Dean and Distinguished
Professor*



Carolyn Seyss,
PharmD, RUCIF
*Fellowship
Executive Director*



Joseph Fulginiti,
PharmD, MBA, RUCIF
RPIF Associate



Erica Dankiewicz,
PharmD, RUCIF
RPIF Consultant



Patrick Park,
PharmD, MBA, RUCIF
RPIF Consultant

Program History

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 26 companies within the pharmaceutical and biopharmaceutical industry with almost 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**.

Well over 1,900 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Professional Development Series

All Fellows gather once monthly as a group to participate in the **Professional Development Day (PDD)** series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

RPIF FOSTERS the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through:

F

Family of Leading Companies

Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.

O

Outstanding Alumni Track Record

Well over 1,900 alumni hold prominent positions at many leading companies, including VP and C-suite levels.

S

Strong Network

Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.

T

Trusted and Proven Since 1984

The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders.

E

Enhanced Career Development

Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.

R

Rigorous Academic Component

Rutgers affiliation provides academic and professional development opportunities.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. **Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.**

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **Wednesday, October 14, 2026** by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:

SUBMIT BY:

Application with short-answer questions

Tuesday, October 20th

Letter of Intent (LOI)

Tuesday, October 20th

Curriculum Vitae (CV)

Tuesday, October 20th

Letters of Recommendation (LORs)

Tuesday, December 1st

ADDRESS LOI AND LORs TO:

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

R | RUTGERS HEALTH
Institute for Pharmaceutical
Industry Fellowships



"My experience as an RPIF Fellow has been one of the most meaningful and transformative parts of my professional journey, providing countless opportunities for growth while reinforcing the importance of giving back to the Ernest Mario School of Pharmacy community. I am grateful to draw upon my nontraditional experiences prior to pharmacy school to mentor, support, and advocate for our RPIF Fellows, encouraging them to embrace their own unique backgrounds as strengths in their professional careers. Investing in their professional and personal development is especially rewarding because today's Fellows will become tomorrow's leaders, advancing innovations that improve the lives of patients and strengthen the communities we serve."

John (Eun Sik) Cho, PharmD
Global GMP QA Strategy



"It is hard to put into words how much this fellowship has meant to me in just my first year. RPIF has challenged me to grow, think differently, and embrace opportunities I never imagined having this early in my career. Knowing that my work has the potential to impact patient care on a global scale has been incredibly rewarding, and I am excited to see how RPIF continues to shape my career and growth as a leader. I encourage future fellows to take advantage of everything the program has to offer because the experiences you gain and the relationships you build will shape your future."

Hillary Anne Reeves, PharmD
Late-Stage Clinical Development



"I am incredibly grateful for the personal and professional growth I have experienced as a Rutgers Fellow. Through RPIF and my partner company, I have been able to learn from inspiring mentors, collaborate with talented peers, and pursue opportunities that have accelerated my development. Being surrounded by such a supportive fellowship community has made this experience especially meaningful and has helped me feel prepared and excited for the future!"

Brynn Gilbert, PharmD
Medical Communications



Aligned First Offer Date
December 11, 2026

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.

